Cardiac Arrest Detectable on Wrist-Worn Device

Why It Matters

The ability to detect shockable cardiac arrests instantly via a consumer‑grade wristband could enable earlier emergency response, potentially improving survival rates. This breakthrough also opens a new market for wearable health tech beyond rhythm monitoring.

Key Takeaways

• Wrist-worn photoplethysmography detected ventricular fibrillation with 100% sensitivity
• Study enrolled 49 patients undergoing ICD implantation or VT ablation
• Overall detection sensitivity was 92% with 86% positive predictive value
• Researchers plan larger trials to reduce false positives in everyday use

Pulse Analysis

Rapid identification of cardiac arrest remains a critical gap in emergency medicine, as every minute without defibrillation reduces survival odds dramatically. Traditional detection relies on bystander observation or implantable devices, limiting coverage to high‑risk populations. Wearable technology, especially photoplethysmography (PPG) sensors embedded in wristbands, offers a ubiquitous platform that continuously monitors blood‑volume changes, making it a promising candidate for early warning systems.

The DETECT‑1b trial provides the first robust clinical validation of a PPG‑based algorithm for shockable cardiac events. Among 49 participants undergoing subcutaneous ICD placement or ventricular tachycardia ablation, the system flagged 92% of induced arrests, achieving perfect sensitivity for ventricular fibrillation and a respectable 86% positive predictive value. These figures surpass earlier laboratory studies that used healthy volunteers, underscoring the algorithm’s resilience in real‑world cardiac pathology. The study also highlighted a higher false‑positive rate, a trade‑off linked to the brief detection windows required for transient arrhythmias.

If manufacturers can refine specificity while preserving sensitivity, wrist‑worn cardiac arrest detectors could transform both consumer health and clinical pathways. Integration with emergency dispatch services would enable automated alerts, shaving precious seconds off response times. However, regulatory approval, data privacy, and reimbursement models will shape adoption. Ongoing DETECT phases aim to test the technology during daily activities and across non‑shockable rhythms, paving the way for a new class of life‑saving wearables that extend beyond fitness tracking into critical care.